
倧éã®ããŒã¿ã蚌æããmRNAã®çœå®³ã
å èšäºã¯ãã¡ããã/Click here to read the original article.
åãããŠãã "ã€ã³ã°ã©ã³ã "ã®mRNAããŒã¿ãéªåŽ©ã®ããã«æŽé²ãããã¯ã¯ãã³æ¥çš®ç¶æ³å¥ã®å šæ»å æ»äº¡çãšã¯ã¯ãã³æ¥çš®çãæ¯èŒã§ããããã«ãªã£ãã
ãã®æ¯èŒã¯ããThe Nobody who Knows Everybodyãã®åã§ç¥ãããSubstackã®èè ã«ãã£ãŠè¡ããã圌ã¯ãã®ããŒã¿ããmRNAçœå®³ã®èšŒæ ã«ãªãããšäž»åŒµããŠããã
èªãããè«ççã§æŠç¥çãªææ³å®¶ã§ãããçŸåšã§ã¯è±éçãªå»åž«ãæ¿æ²»å®¶ãšã亀æµãããããšç§°ãããã®èè ã¯ãã宿å£äœãä¿å¥åœå±ãå»çåŸäºè ãæ¿æ²»å®¶ãè¬å±çµå¶è ãçµ±èšåŠè ãè£å€å®ããããã¯ãããã倧人ã¯ãä»ãmRNAããå°å瀟äŒãå®ã矩åãããããšæžããŠããã圌ãããªããã®ãããªçµè«ã«è³ã£ããã以äžã®èäœã§ç€ºããŠããã
mRNAãã£ã¶ã¹ã¿ãŒã®èšŒæïŒ
以äžã®ã°ã©ãã¯ã"ã€ã³ã°ã©ã³ã "ã®18æ³ä»¥äžã®æäººã«ãããã¯ã¯ãã³æ¥çš®çãšãå人å£ã®åã¯ã¯ãã³æ¥çš®ã°ã«ãŒããå ããå šæ»å æ»äº¡ã®å²åã瀺ããŠããã
ã€ã³ã°ã©ã³ã "ã®ã¯ã¯ãã³æåã°ã«ãŒã
ã¯ã¯ãã³æªæ¥çš®
1åæ¥çš®ä»¥äž
2å以äž
3å以äž
ç§ãã¡ãæ±ã£ãŠãããµã³ãã«ãµã€ãºã¯ãã€ã³ã°ã©ã³ãã®18æ³ä»¥äžã®æäººäººå£ã§ãããããã¯5,000äžäººãè¶
ãããµã³ãã«ãµã€ãºã§ããã
Covid-19ãmRNAãããŒã¹ã®ã¯ã¯ãã³ãšãã®å±éã¯ãããŒã¿ããã³ãã®è§£éãšæ¯èŒããã°äºçްãªãµã³ãã«æ°ã«åºã¥ããŠãããç¡å
è²¬è²©å£²ã§æ°ååã®å©çãåŸãç«å Žã«ããäŒæ¥ã«ãã£ãŠç®¡çãããŠããã
ã°ã©ãã¯3ã€ã®ã·ããªãªã®ãã¡ã®1ã€ã衚ããŠããïŒ
ã·ããªãª1
ãã¯ã¯ãã³æ¥çš®ãã¯ãïŒããããåå ã«ããïŒæ»äº¡ã®å¯èœæ§ã«ãŸã£ãã圱é¿ãäžããŸãããããéå£ã«ãããã¯ã¯ãã³æ¥çš®ã®å²åãšãåãéå£ã«ãããïŒããããåå ã«ããïŒæ»äº¡ã®å²åãèŠããšããã®å²åã¯åçŽã«äžèŽããã
äŸ: 人å£10äžäººã®å Žå
人å£ã®85ïŒ
ãã¯ã¯ãã³æ¥çš®ãåããŠããã
ããæã«ïŒããããåå ã§ïŒ100äººãæ»äº¡ããã
æ»äº¡è
ã®85ïŒ
ã¯ã¯ã¯ãã³ãæ¥çš®ãã人ïŒ85人ïŒã§ãã-ããã¯ã¯ã¯ãã³æ¥çš®è
ã®äººå£ã®85ïŒ
ãšåãã§ããã
100äººã®æ»äº¡è
ã®ãã¡15ïŒ
ã¯ã¯ã¯ãã³æªæ¥çš®è
ã§ããã
*éèŠ*
ããªããæã£ãŠããã®ãšã¯å察ã«ããžã§ããŒã»ãã§ã«ã·ãŒã«é¢ããæ
å ±ãèŠã€ããã®ã¯ãšãŠãé£ããã
ã·ããªãª2
ãã¯ã¯ãã³æ¥çš®ãã¯ïŒããããåå ã§ïŒæ»äº¡ããå¯èœæ§ãæžå°ãããã
ããéå£ã«ãããã¯ã¯ãã³æ¥çš®ã®å²åãšãåãéå£ã«ãããïŒããããåå ã«ããïŒæ»äº¡ã®å²åãæ¯èŒãããšãã¯ã¯ãã³æ¥çš®ãåããéå£ã®æ¹ãæ»äº¡ã®å²åãäœãã
äŸ: 人å£10äžäººã®å Žå
人å£ã®85ïŒ
ãã¯ã¯ãã³æ¥çš®ãåããŠããã
ããæã«100äººãæ»äº¡ããïŒãã¹ãŠã®åå ã«ããïŒã
æ»äº¡è
ã®75ïŒ
ã¯ã¯ã¯ãã³æ¥çš®è
ïŒ75人ïŒã§ããã
100äººã®æ»äº¡è
ã®ãã¡25ïŒ
ã¯ã¯ã¯ãã³æªæ¥çš®è
ã§ããã
*éèŠ*
ã¯ã¯ãã³æ¥çš®åãšæ¯èŒãããšããã®ã·ããªãªã§ã¯æ»äº¡è
æ°ïŒå
šæ»å ïŒã®å¢å ã¯æåŸ
ã§ããªãã
ã·ããªãª3
ãã¯ã¯ãã³æ¥çš®ãã¯å®å
šã§ã广çã§ããªããæ»äº¡ããå¯èœæ§ãå¢å ãããïŒãã®ãããªè£œåã®äžè¬ãžã®çºå£²ã远跡ããéå°ãªæ»äº¡ã説æãã仮説*ã§ããããã®æè¡ã«å«ãŸãããªã¹ã¯ã®å€§ããããäºæž¬ããããšããã§ããïŒïŒ
ããéå£ã«ãããã¯ã¯ãã³æåã®å²åãšãåãéå£ã«ãããïŒããããåå ã«ããïŒæ»äº¡ã®å²åãæ¯èŒãããšãã¯ã¯ãã³ãæ¥çš®ããŠããéå£ã®æ¹ãæ»äº¡ã®å²åãé«ãã
ããã¯çœé£ã§ããïŒ
ãã®çœå®³ã·ããªãªã«åèŽããäŸïŒ
人å£10äžäºº
人å£ã®85ïŒ
ãã¯ã¯ãã³æ¥çš®ãåããŠãã
ããæã«ïŒããããåå ã§ïŒ100äººãæ»äº¡ããã
æ»äº¡è
ã®95ïŒ
ã¯ã¯ã¯ãã³ãæ¥çš®ãã人ïŒ95人ïŒã§ããã
100äººã®æ»äº¡è
ã®ãã¡5ïŒ
ã¯ã¯ã¯ãã³æªæ¥çš®è
ã§ããã
*éèŠ*
ããã«ãã¯ã¯ãã³æ¥çš®ã®çœå®³ã·ããªãªã§ã¯ãæ¥çš®åæ°ãå¢ããããšã«ãåã¯ã¯ãã³æ¥çš®çŸ€ã«ãããå šæ»å æ»äº¡è ã®å²åãäžé£ãåãã«é«ããªã£ãŠããããšãäºæ³ãããã
以äžã¯ãè±åœæ¿åºã®ããŒã¿éªåŽ©ã3ã€ã®ç°¡åãªã°ã©ãã«ãããã®ã§ããã
æ¿åºããŒã¿ãäœæããããã«å
±è¬ããããšã¯ã§ããªãã
SCENARIO 3ã¯éåžžã«æç¢ºã§ããã
1å以äžã®æäžã¯æªã

2å以äžã®æäžã¯ããæªã

3å以äžã®æäžã¯ããæªã

ããŒã¿æº
ç¹å®éå£ã®ã¯ã¯ãã³æ¥çš®ç¶æ³å¥å
šæ»å æ»äº¡æ°
è±åœåœå®¶çµ±èšå±
ãè±åœæå€§ã®ç¬ç«ç³»å ¬ççµ±èšæ©é¢ãåœãå°åãå°æ¹ã¬ãã«ã®çµæžã人å£ã瀟äŒã«é¢ããçµ±èšã®åéãšå ¬è¡šãæ åœããŠããããŸãã10幎ããšã«ã€ã³ã°ã©ã³ããšãŠã§ãŒã«ãºã§åœå¢èª¿æ»ã宿œããŠãããã
6 2022幎7æã¬ããŒã 2021幎1æ1æ¥ãã2022幎5æ31æ¥ãŸã§ã®æ»äº¡è
æ°
2023 幎 8 æ 25 æ¥ å ±åæžïŒ 2021幎4æ1æ¥ãã2023幎5æ31æ¥ãŸã§ã®æ»äº¡è
æ°
ãã®2ã€ã®å ±åæžã¯ã2021幎1æããã®ã¯ã¯ãã³å±éæéäžã®å
šæ»å æ»äº¡ããŒã¿ãšããŠãããŸãšãŸã£ãŠããã
ããŒã¿ãœãŒã¹
ç¹å®éå£ã®ã¯ã¯ãã³æ¥çš®ç
UKHSA Fortnightly National Influenza and COVID-19 Reportã®å¥¥æ·±ãã«ããã
ãå
šåœã€ã³ãã«ãšã³ã¶ããã³COVID-19ãµãŒãã€ã©ã³ã¹ããŒã¿å ±åæžïŒ 2023幎7æ6æ¥ïŒç¬¬27é±ïŒãã
è±åœæ¿åºã®ãŠã§ããµã€ãã¯ãã¡ã
å®éã®ããŒã¿ã¯è£è¶³ã®ODSåãã¡ã€ã«ã«åãããŠããïŒãšã¯ã»ã«ã§éãããšãã§ããïŒ
ãã®ODSããŒã¿ãã¡ã€ã«ã¯ãèŠãã¹ãå Žæãç¥ã£ãŠããã°ããããŸã§äºå®äžäžè¬ã«ç¥ãããããšã®ãªãã£ãããŒã¿ãä¿æããŠããã
"Figure_19__COVID_Vac_Uptake "ãšãããããã«ããã¿ãïŒãã®ããŒã¿ãã¡ã€ã«ã®40以äžã®ã¿ãã®ãã¡ã®ã²ãšã€ïŒãããã
第27é±å ±åæžã®å³19ãèŠãéãããã®å ±åæžãäœæããçµç¹ã® "å€éš "ã®äººéãããã®çµç¹ãšååããŠãã人éãããã®éèŠãªæ¯èŒããŒã¿ãæ¢ãããšãç¥ãã¯ãããªãã
ãã®ç¹ã以äžã«ç€ºãïŒ

å ±åæžã®å³19ã¯ã2023幎æ¥ã®ããŒã¹ã¿ãŒã®75æ³ä»¥äžãšå ç«æå¶è ã®ã¯ã¯ãã³æåã«çŠç¹ãåœãŠãŠããããšã瀺ããŠããã ãã§ããã
ããããåãããããããªãã¯ã»ãã¡ã€ã³ãã«ãããã®è¡šã®ããŒã¿ã«ã¯ãããããªãã¯ã»ãã¡ã€ã³ãã«æ·±ãåãããæ å ±ã®ãŸãŸã§ããããã¯ããããéèŠã§ãããå ¬éãããªããã°ãªããªããã®ã·ãŒãã®ããŒã¿ãå«ãŸããŠããïŒ ãã¡ã€ã«ãªã³ã¯ïŒç¬¬27é±å ±åæž ã¯ã¯ãã³æ¥çš®ç
ããŒã¿ãã¡ã€ã«
äžèšã®3ã€ã®ããŒã¿ãã¡ã€ã«ã¯ãçŸåšã®å Žæãã倿ŽãŸãã¯åé€ãããå ŽåããŸãä»ã®äººãç°¡åã«ããŠã³ããŒãã§ããããã«ããã®Substackã«ãã¢ããããŒããããŠããŸãã
åç §è¡š06072022ã¢ã¯ã»ã¹å¯èœ 538KBâ XLSXãã¡ã€ã« ããŠã³ããŒã
åç §è¡šaug2023 887KBã»XLSXãã¡ã€ã« ããŠã³ããŒã
é±åã€ã³ãã«ãšã³ã¶ã»Covid19ã¬ããŒãããŒã¿ å€W27ã¬ããŒã 1.09MB ã» XLSXãã¡ã€ã« ããŠã³ããŒã
æåŸã®ãã¡ã€ã«ã¯ãSubstackãODSãã¡ã€ã«ããµããŒãããŠããªããããExcelãã¡ã€ã«ã«å€æãããã®ã§ãã
以äžã®3ã€ã®ãã¡ã€ã«ã¯ãäžèšã®3ã€ã®ãã¡ã€ã«ã«ã€ããŠãã¯ãŒã¯ã·ãŒãå ã®é¢é£ããã·ãŒãã«åã远å ããäžèšã®éèŠãªãã£ãŒãã®ããã«ããŒã¿ãæŽçããæå³ã®ããäžé£ã®é¢é£ããŒã¿ã«è¡šç€ºãããã®ã§ããã
ããŒã¿ãã¡ã€ã« ã¯ãŒãã³ã°ïŒ
Referencetable06072022accessible ã·ãŒãã»ããŒãã«2äžã®ã¯ãŒã¯ã¹ã§ Lå以éãåç § 794KBâXLSX ãã¡ã€ã«ã»ããŠã³ããŒã
åç §è¡šaug2023 ã·ãŒã衚2ã®ã¯ãŒã¯ã¹ã§Lå以éãåç § 1.58MB ã» XLSXãã¡ã€ã« ããŠã³ããŒã
é±åã€ã³ãã«ãšã³ã¶ããã³Covid19ã¬ããŒãã»ããŒã¿ å€ã®W27ã¬ããŒãïŒã·ãŒãäžã®ã¯ãŒã¯ä»ãïŒ å³19 Covid Vacã®æåé 远å ã«ã©ã Et以éãåç § 1.29MBâ XLSXãã¡ã€ã« ããŠã³ããŒã
ã³ã³ãã€ã«ãããããŒã¿ãã¡ã€ã«ïŒ
UKã¯ã¯ãã³ãšæ»äº¡ããŒã¿ã»ããïŒ2021幎1æãã2023幎5æãŸã§ã®CharatsããŒã¿çšïŒ 51.9KBâ XLSXãã¡ã€ã« ããŠã³ããŒã
*仮説
ãã¯ã¯ãã³æ¥çš®ãã¯å®å
šã§ã广çã§ããªã
Covid-19 mRNAã¯ã¯ãã³ã¯ãæ£ç¢ºã«ã¯ãªãããã»ããç²ååæã¡ãã»ã³ãžã£ãŒRNAéºäŒåæå°è£œåã§ããã以äžã®ã¯ã€ã«ãã«ãŒããæã£ãŠããïŒ
i) ççæ§ã®é«ãè質ããç²åïŒLNPïŒã®ééã·ã¹ãã
ii) LNPã®å¶åŸ¡ãããªãå
šèº«ãžã®çäœå
ååž
iii) LNPã¯ãåæã¡ãã»ã³ãžã£ãŒRNAã®åœ¢ã§éºäŒååœä»€ãéã¶ã
iv) åæã¡ãã»ã³ãžã£ãŒRNAã®æ§è³ªã«ã¯ã次ã®ãããªæ¢ç¥ã®ãªã¹ã¯ãããã
a) åæã¡ãã»ã³ãžã£ãŒRNAã¯ãèªç¶çã®ã¡ãã»ã³ãžã£ãŒRNAãããæ¡éãã«é·ããã¿ã³ãã¯è³ªãç£çããåœä»€ã®å¶åŸ¡äžèœãªé·å¯¿åœãæã£ãŠããã
åºä¹³é¡ãé²åããŠããããã«ãçåœã«ã¯ã¿ã³ãã¯è³ªãç£çããã¡ãã»ã³ãžã£ãŒRNAã®èªç¶ãªåæ¢ã¹ã€ãããããã
b) ã¯ãŒãé床ã§è£œé ãããåæã¡ãã»ã³ãžã£ãŒRNAã¯ããã¡ã€ã¶ãŒãã¢ããã®ç ç©¶æãè£œé æœèšãšã¯æ¯èŒã«ãªããªãçŽåºŠã§äœå
ã®æ žã®å¥¥æ·±ãã§è£œé ããã倩ç¶ã¡ãã»ã³ãžã£ãŒRNAã«æ¯ã¹ã人éã®å·¥å Žç°å¢ããæ¥ãæçåãããéºäŒçæç€ºãæã€ã
c) åæã¡ãã»ã³ãžã£ãŒRNAã®ç¡å¶éãªçäœå
ååžã«ããããã«ã¢ã³ãé
µçŽ ã®ãããªå€©ç¶ã¿ã³ãã¯è³ªãçç£ããç¹çްãªã·ã¹ãã ãšã¹ã±ãžã¥ãŒã«ãç¶æããããã«ããã§ã«ç®èº«çã«åããŠããäœå
šäœãšãã®æ§ã
ãªçްèã¿ã€ãã«ãäœåãªã¿ã³ãã¯è³ªãçç£ããè² æ
ãç¡éã«ãããã
v) åæã¡ãã»ã³ãžã£ãŒRNAã®éºäŒçåœä»€ã¯ãæ¢ç¥ã®æåïŒCovid-19 Spike ProteinïŒãç£çããåœä»€ã§ãããè¡ç®¡çãèªå·±å
ç«åå¿ã®åå ãšããŠç¥ãããŠããããã®æç€ºãšå¶åŸ¡ãããŠããªãçäœå
ååžãšã®çµã¿åããã¯ãçœããããããããšãäºæž¬ã§ããïŒ
èŠå¶åœå±ã倱æããéªåŽ©ã®ãããªããŒã¿ãéãŸãã°ãæ»äº¡ãå
¥é¢ãšãã圢ã§çŸããã§ãããã
vi) é·æå®å
šæ§ããŒã¿ããªãã管çãããŠããªããã®ãæªç¥ã®ãã®ã身äœã®èªç¶ãªãã©ã³ã¹ããåãé¢ããããã®ã®çµã¿åãããèãããšãååãªå®å
šæ§ããŒã¿ãåŸãã«ã¯ãããšãäœååãã®ã¢ã«ã¢ããã䜿ã£ããšããŠããå幎ã¯ãããã ããã

ããŒã¿æçè«è ãšãã€ããŒããªmRNAæè³å®¶ïŒã«ãã«ã®ããã«ïŒ
æ°Žãæ¿ããããªè©Šã¿ããªãããç·šéãããããŒã¿ã«ã¯å€§ããªã°ãã€ããæ¯éå£ã®éãããããšãã䞻匵ããªãããã ããã
ãã®ã©ãããæããå
ã«èãããããããŒã¿ãç°ãªãå°åãç°ãªãéå£ã®ããã«åããããšããèããããã«ææããããšã¯ã§ããªãã ããïŒ
ããŒã¿ãœãŒã¹
ç¹å®éå£ã®ã¯ã¯ãã³æ¥çš®ç¶æ³å¥å
šæ»å æ»äº¡æ°
è±åœåœå®¶çµ±èšå±ïŒONSïŒ
äž¡ãã¡ã€ã«ã®è¡šçŽã«ã¯
"ã¯ã¯ãã³æ¥çš®ç¶æ³å¥æ»äº¡ã®å¹Žéœ¢æšæºåæ»äº¡çãã€ã³ã°ã©ã³ã"
ãŸããå ±åãããæ»äº¡è
æ°ã¯18æ³ä»¥äžã«éå®ãããŠããã
ONSã«ã¯æ¬¡ã®ãã㪠"User guide to mortality statistics "ãããã
ãã®ã¬ã€ãã®ç¬¬5ç« ã«ã¯ããããïŒ
ãå
¬è¡šãããæ»äº¡çµ±èšã¯ãã€ã³ã°ã©ã³ããšãŠã§ãŒã«ãºã§ç»é²ãããæ»äº¡ã«åºã¥ããã®ã§ãããããã€ã³ã°ã©ã³ããšãŠã§ãŒã«ãºã§æ»äº¡ããå Žåãè±åœä»¥å€ã®åœã®å±
äœè
ã蚪åè
ã®æ»äº¡ãå«ãŸããã
ãã®ããšãæ¯èŒæ¯éå£ã«ã©ã®çšåºŠåœ±é¿ããããèŠãããã«ããã®ããšãå ±åãããæ»äº¡æ°ã«0.1ïŒ
ãã0.2ïŒ
圱é¿ããããšã瀺ã衚ãäœæãããŠããã

ããŒã¿ãœãŒã¹
ç¹å®éå£ã®ã¯ã¯ãã³æ¥çš®ç
å³ 19 ã«ããããã«ããã®ããŒã¿ã®æ¯éå£ã¯ "ã€ã³ã°ã©ã³ãåšäœè
"ã§ããã
ããã«ãããŒã¿ã¯å¹Žéœ¢å¥ã«åããããŠãããã¯ã¯ãã³æ¥çš®ç¶æ³å¥å
šæ»å æ»äº¡ããŒã¿ã»ãããšäžèŽããããã«ã䜿çšããããŒã¿ã18æ³ä»¥äžã«éå®ããããšãå¯èœã§ãã£ãã
ç§ãã¡ã®èº«äœã®éºäŒåãããã«ããªã±ãŒãã§ãããããããŠãæç¶æéãäžæãçäœå ååžãäžæãèªç¶ã®çŽåºŠããã®éžè±ãäžæããã¹ãŠã®çްèã¿ã€ããããããã®çްèã¿ã€ãã«äŸåãã身äœã«é¢é£ããæ©èœãžã®åœ±é¿ãäžæãªéºäŒçæç€ºããå¹²æžãªãã«ããããŠããããã®åæå€æ¥ã¿ã³ãã¯è³ªãçºçŸããèªèº«ã®çްèãç°¡åã«æ»æãããããšãã§ããåæå€æ¥ã¿ã³ãã¯è³ªã®ç£çãªãã«å±éããããšãããã«ç¡è¬ã§ããããçè§£ããã®ã«åœ¹ç«ã€ã